Washington

Overview

Washington legalized medical cannabis on November 3, 1998 via Initiative 692 (the Medical Use of Marijuana Act), one of the first state medical-cannabis programs in the country. Adult-use cannabis was legalized via Initiative 502 of November 6, 2012, alongside Colorado's Amendment 64. Licensed adult-use retail sales began July 8, 2014, making Washington and Colorado the first two U.S. states with operational adult-use commercial retail.

The Washington State Liquor and Cannabis Board (LCB) regulates adult-use licensing, cultivation, processing, and retail. The Washington State Department of Health (DOH) administers the Medical Marijuana Authorization Database.

Adult-use (Initiative 502, 2012)

Adults 21 and older may possess 1 oz of cannabis flower, 16 oz of infused solids, 72 oz of infused liquids, or 7 g of concentrate. Home cultivation for recreational use is prohibited; Washington is one of the few adult-use states without a personal recreational grow allowance. Adult-use cannabis is taxed at 37% state excise at retail plus standard state and local sales tax.

Medical program (Initiative 692, 1998)

Qualifying conditions

Initiative 692 and subsequent amendments enumerate qualifying conditions including cancer, HIV/AIDS, multiple sclerosis with intractable spasticity, epilepsy and seizure disorders, glaucoma, Crohn's disease, hepatitis C with debilitating nausea or intractable pain, intractable pain, and any other terminal or debilitating condition meeting program criteria.

Patient access

Registered patients on the Washington Medical Marijuana Authorization Database may possess 3 oz of flower, 48 oz of infused solids, 216 oz of liquid product, or 21 g of concentrate. Listed patients receive a recognition card valid for sales-tax exemption on medical purchases. Adult-use possession of 1 oz of flower also applies.

Patient registration steps

1. Schedule a visit with a Washington-licensed healthcare provider authorized to recommend medical cannabis.
2. The provider issues a written Medical Marijuana Authorization.
3. The patient takes the authorization to a medically endorsed cannabis retailer.
4. Retailer staff enters the patient into the state Medical Marijuana Authorization Database.
5. Listed patients receive a recognition card valid for tax exemption and higher possession allowances.

Patients and caregivers

• Patient minimum age: 18. Minor patients require a designated caregiver (parent or legal guardian) plus practitioner authorization.
• Caregiver minimum age: 21.
• Caregivers per patient: typically up to 1 designated caregiver per patient.
• Cooperative cultivation: registered patients may form cooperatives of up to 4 patients with combined cultivation of up to 60 plants among them.
• Caregiver registration: through the DOH Medical Marijuana Authorization Database; background check.

Home cultivation

Registered medical patients may grow up to 6 plants per patient, with a household cap that can extend to 15 plants when documented in the database. Recreational home cultivation remains prohibited for adult-use consumers. Plants must be kept secure and out of public view.

Reciprocity

Washington does not formally recognize out-of-state medical cards for the medical-program tax exemption. Visiting adults 21 and older may purchase from any licensed adult-use retailer with a valid government ID, subject to standard adult-use possession limits.

Employment protections

Washington's SB 5123 (effective January 1, 2024) prohibits most pre-employment cannabis testing for non-safety-sensitive positions. Employers may still test for current impairment and may maintain drug-free workplace policies. Safety-sensitive positions (transportation, law enforcement, certain federal contractors) remain subject to standard pre-employment testing.

Recent developments (2025-2026)

Washington continued LCB rulemaking through 2025-2026 on labeling, potency caps, and licensee-disclosure rules. Bills addressing intoxicating-hemp regulation advanced in the 2026 session alongside the broader state-federal hemp-cannabinoid policy reckoning. Patient-registry expansion to non-physician prescribers (NPs, PAs) remained under LCB administrative review.

Hemp and CBD legality

Washington's industrial-hemp program operates under RCW 15.140 through the Washington State Department of Agriculture (WSDA) in alignment with the 2018 Federal Farm Bill (0.3% delta-9 THC by dry weight). Industrial-hemp CBD and other non-intoxicating hemp products are lawful at general retail subject to WSDA labeling.

The defining intoxicating-hemp legislation was SB 5367 of 2023, signed by Governor Inslee and effective July 23, 2023. SB 5367 classifies hemp-derived intoxicating cannabinoids — including delta-8 THC, delta-9 THC from hemp, delta-10 THC, THC-O, HHC, and similar synthetic or chemically-converted isomers — as cannabis subject to Washington State Liquor and Cannabis Board (WSLCB) regulatory authority. These products may be sold only through WSLCB-licensed cannabis retailers, where they are tested, labeled, age-gated to 21+, and taxed identically to other cannabis products. Non-cannabis retail sale of intoxicating-hemp products is prohibited.

The legislation was driven by youth-access concerns about delta-8 vape products marketed in convenience-store packaging that closely resembled regulated cannabis. WSLCB issued implementing rules in 2024 (Chapter 314-55 WAC amendments) clarifying per-serving total-THC thresholds, lab-testing methodology (Oregon's ORELAP-accreditation model adapted for Washington), and licensee disclosure requirements. The 2026 legislative session considered additional refinements to enforcement and per-serving caps.

Smokable hemp flower at retail is restricted under the same total-THC framework as intoxicating cannabinoids. WSDA continues to administer industrial-hemp production licensing for fiber, seed, and CBD purposes; the WSDA and WSLCB jointly issued operator guidance in 2024 clarifying the regulatory line between industrial hemp and intoxicating-hemp products. Informational only — not legal advice.